What is Heparin and Its Medical Uses
Heparin is an anticoagulant medication derived from porcine intestinal mucosa that works by enhancing antithrombin activity to prevent and treat blood clots, with established efficacy in venous thromboembolism, acute coronary syndromes, and prevention of clotting during cardiac procedures and dialysis. 1
What Heparin Is
Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides (glycosaminoglycans) with potent anticoagulant properties 1. The pharmaceutical preparation is a sterile solution standardized for anticoagulant activity, administered intravenously or subcutaneously. It functions by binding to antithrombin (AT), creating a complex that inactivates thrombin and factor Xa, thereby interrupting the coagulation cascade 2.
Primary Medical Uses
Venous Thromboembolism
Heparin is highly effective for both prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) 2. The evidence base includes randomized controlled trials involving over 15,000 patients demonstrating safety and efficacy 2.
Dosing regimens:
- Prophylaxis: 5,000 U subcutaneously every 8-12 hours 2
- Treatment: 5,000 U IV bolus followed by 32,000 U per 24 hours by continuous IV infusion, adjusted to maintain aPTT in therapeutic range (1.5-2.5 times control) 2
Acute Coronary Syndromes
For unstable angina and acute MI, heparin reduces cardiovascular death and MI by approximately 30% when combined with aspirin 2. Heparin is always used in combination with aspirin in acute myocardial ischemia, never as monotherapy 2.
Dosing for coronary disease:
- Unstable angina or acute MI without thrombolysis: 5,000 U IV bolus followed by 32,000 U per 24 hours IV infusion 2
- After thrombolytic therapy: 5,000 U IV bolus followed by 24,000 U per 24 hours (though benefits are questioned when aspirin is co-administered) 2
Additional FDA-Approved Indications
Heparin is indicated for 1:
- Prevention of postoperative DVT/PE in patients undergoing major abdominothoracic surgery
- Atrial fibrillation with embolization
- Acute and chronic disseminated intravascular coagulation
- Prevention of clotting in arterial and cardiac surgery
- Peripheral arterial embolism prophylaxis and treatment
- Anticoagulation during blood transfusions, extracorporeal circulation, and dialysis
Monitoring Requirements
Therapeutic monitoring is essential due to significant inter-patient variability 2. Target aPTT should be 1.5-2.5 times control, equivalent to heparin levels of 0.2-0.4 U/mL by protamine titration or anti-factor Xa levels of 0.30-0.7 U/mL 2.
For patients at risk of heparin-induced thrombocytopenia (HIT) >1%: Monitor platelet counts every 2-3 days from day 4 to day 14 3. This is critical as HIT can lead to devastating thromboembolic complications including pulmonary embolism, limb ischemia requiring amputation, MI, and stroke 3.
Important Clinical Caveats
Bleeding Risk
Bleeding is the chief complication of heparin therapy 1. Patients over 60 years, particularly women, have higher bleeding incidence and may require lower doses 1. When bleeding occurs, protamine sulfate (1% solution) neutralizes heparin—each mg neutralizes approximately 100 USP units, administered slowly (maximum 50 mg per 10 minutes) 1.
Pediatric Considerations
Use only preservative-free heparin in neonates and infants 1. Benzyl alcohol-containing preparations have caused fatal "gasping syndrome" in premature neonates, with serious adverse reactions including neurological deterioration, seizures, intracranial hemorrhage, and cardiovascular collapse 1.
Obesity Adjustment
Recent evidence shows obese patients require lower weight-adjusted heparin doses to achieve target ACT, with significant variability in therapeutic effect 4. Body mass index is the only significant covariate affecting heparin response after weight-based dosing 4.
Limitations
Heparin has reduced efficacy at sites of deep arterial injury because fibrin-bound thrombin is protected from inhibition by the heparin-antithrombin complex 2. This explains why direct thrombin inhibitors like hirudin may be more effective in certain acute coronary syndrome scenarios 2.